A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 19 May 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2017 Planned End Date changed from 1 May 2017 to 15 Jun 2017.